Hepatitis delta infection among persons living with HIV in Europe
| Title: | Hepatitis delta infection among persons living with HIV in Europe |
|---|---|
| Authors: | Beguelin C.; Atkinson A.; Boyd A.; Falconer K.; Kirkby N.; Suter-Riniker F.; Gunthard H. F.; Rockstroh J. K.; Mocroft A.; Rauch A.; Peters L.; Wandeler G.; Abela I.; Aebi-Popp K.; Anagnostopoulos A.; Battegay M.; Bernasconi E.; Braun D. L.; Bucher H. C.; Calmy A.; Cavassini M.; Ciuffi A.; Dollenmaier G.; Egger M.; Elzi L.; Fehr J.; Fellay J.; Furrer H.; Fux C. A.; Hachfeld A.; Hasse B.; Hirsch H. H.; Hoffmann M.; Hosli I.; Huber M.; Kaiser L.; Keiser O.; Klimkait T.; Kouyos R. D.; Kovari H.; Martinetti G.; Martinez de Tejada B.; Marzolini C.; Metzner K. J.; Muller N.; Nemeth J.; Nicca D.; Paioni P.; Pantaleo G.; Perreau M.; Schmid P.; Speck R.; Stockle M.; Tarr P.; Trkola A.; Yerly S.; Harxhi A.; Losso M.; Kundro M.; Schmied B.; Zangerle R.; Karpov I.; Vassilenko A.; Mitsura V. M.; Paduto D.; Clumeck N.; De Wit S.; Delforge M.; Florence E.; Vandekerckhove L.; Hadziosmanovic V.; Begovac J.; Machala L.; Jilich D.; Sedlacek D.; Kronborg G.; Benfield T.; Gerstoft J.; Kirk O.; Pedersen C.; Johansen I. S.; Ostergaard L.; Wiese L.; Nielsen L. N.; Zilmer K.; Smidt J.; Siseklinik N.; Aho I.; Viard J. -P.; Lacombe K.; Pradier C.; Fontas E.; Duvivier C.; Rockstroh J.; Degen O.; Hoffmann C.; Stellbrink H. J.; Stefan C.; Bogner J.; Fatkenheuer G.; Chkhartishvili N.; Sambatakou H.; Adamis G.; Paissios N.; Szlavik J.; Gottfredsson M.; Devitt E.; Tau L.; Turner D.; Burke M.; Shahar E.; Wattad L. M.; Elinav H.; Haouzi M.; Elbirt D.; D'Arminio Monforte A.; Guaraldi G.; Esposito R.; Mazeu I.; Mussini C.; Mazzotta F.; Gabbuti A.; Lazzarin A.; Castagna A.; Gianotti N.; Galli M.; Ridolfo A.; Uzdaviniene V.; Matulionyte R.; Staub T.; Hemmer R.; van der Valk M.; Trajanovska J.; Reikvam D. H.; Maeland A.; Bruun J.; Knysz B.; Szetela B.; Inglot M.; Bakowska E.; Flisiak R.; Grzeszczuk A.; Parczewski M.; Maciejewska K.; Aksak-Was B.; Beniowski M.; Mularska E.; Jablonowska E.; Kamerys J.; Wojcik K.; Mozer-Lisewska I.; Rozplochowski B.; Zagalo A.; Mansinho K.; Maltez F.; Radoi R.; Oprea C.; Gusev D.; Trofimova T.; Khromova I.; Kuzovatova E.; Borodulina E.; Vdoushkina E.; Ranin J.; Tomazic J.; Miro J. M.; Laguno M.; Martinez E.; Garcia F.; Blanco J. L.; Martinez-Rebollar M.; Mallolas J.; Callau P.; Rojas J.; Inciarta A.; Moreno S.; del Campo S.; Clotet B.; Jou A.; Paredes R.; Puig J.; Llibre J. M.; Santos J. R.; Domingo P.; Gutierrez M.; Mateo G.; Sambeat M. A.; Laporte J. M.; Novak P.; Thalme A.; Sonnerborg A.; Brannstrom J.; Flamholc L.; Kusejko K.; Braun D.; Kuznetsova A.; Mikhalik J.; Sluzhynska M.; Milinkovic A.; Johnson A. M.; Edwards S.; Phillips A.; Johnson M. A.; Orkin C.; Winston A.; Clarke A.; Leen C.; Lundgren J.; Rasmussen L. D.; Kowalska J. D.; Larsen J. F.; Neesgaard B.; Jaschinski N.; Fursa O.; Raben D.; Kristensen D.; Fischer A. H.; Jensen S. K.; Elsing T. W.; Gardizi M.; Ahmed A.; Reekie J.; Cozzi-Lepri A.; Pelchen-Matthews A.; Roen A.; Tusch E. S.; Bannister W. |
| Contributors: | Beguelin, C.; Atkinson, A.; Boyd, A.; Falconer, K.; Kirkby, N.; Suter-Riniker, F.; Gunthard, H. F.; Rockstroh, J. K.; Mocroft, A.; Rauch, A.; Peters, L.; Wandeler, G.; Abela, I.; Aebi-Popp, K.; Anagnostopoulos, A.; Battegay, M.; Bernasconi, E.; Braun, D. L.; Bucher, H. C.; Calmy, A.; Cavassini, M.; Ciuffi, A.; Dollenmaier, G.; Egger, M.; Elzi, L.; Fehr, J.; Fellay, J.; Furrer, H.; Fux, C. A.; Hachfeld, A.; Hasse, B.; Hirsch, H. H.; Hoffmann, M.; Hosli, I.; Huber, M.; Kaiser, L.; Keiser, O.; Klimkait, T.; Kouyos, R. D.; Kovari, H.; Martinetti, G.; Martinez De Tejada, B.; Marzolini, C.; Metzner, K. J.; Muller, N.; Nemeth, J.; Nicca, D.; Paioni, P.; Pantaleo, G.; Perreau, M.; Schmid, P.; Speck, R.; Stockle, M.; Tarr, P.; Trkola, A.; Yerly, S.; Harxhi, A.; Losso, M.; Kundro, M.; Schmied, B.; Zangerle, R.; Karpov, I.; Vassilenko, A.; Mitsura, V. M.; Paduto, D.; Clumeck, N.; De Wit, S.; Delforge, M.; Florence, E.; Vandekerckhove, L.; Hadziosmanovic, V.; Begovac, J.; Machala, L.; Jilich, D.; Sedlacek, D.; Kronborg, G.; Benfield, T.; Gerstoft, J.; Kirk, O.; Pedersen, C.; Johansen, I. S.; Ostergaard, L.; Wiese, L.; Nielsen, L. N.; Zilmer, K.; Smidt, J.; Siseklinik, N.; Aho, I.; Viard, J. -P.; Lacombe, K.; Pradier, C.; Fontas, E.; Duvivier, C.; Rockstroh, J.; Degen, O.; Hoffmann, C.; Stellbrink, H. J.; Stefan, C. |
| Publisher Information: | John Wiley and Sons Inc |
| Publication Year: | 2023 |
| Subject Terms: | HCC; Hepatitis Delta; HIV; PLWH; prevalence |
| Description: | Background and Aims: A high prevalence of hepatitis delta virus (HDV) infection, the most severe form of viral hepatitis, has been reported among persons living with HIV (PLWH) in Europe. We analysed data from a large HIV cohort collaboration to characterize HDV epidemiological trends across Europe, as well as its impact on clinical outcomes. Methods: All PLWH with a positive hepatitis B surface antigen (HBsAg) in the Swiss HIV Cohort Study and EuroSIDA between 1988 and 2019 were tested for anti-HDV antibodies and, if positive, for HDV RNA. Demographic and clinical characteristics at initiation of antiretroviral therapy were compared between HDV-positive and HDV-negative individuals using descriptive statistics. The associations between HDV infection and overall mortality, liver-related mortality as well as hepatocellular carcinoma (HCC) were assessed using cumulative incidence plots and cause-specific multivariable Cox regression. Results: Of 2793 HBsAg-positive participants, 1556 (56%) had stored serum available and were included. The prevalence of HDV coinfection was 15.2% (237/1556, 95% confidence interval [CI]: 13.5%–17.1%) and 66% (132/200) of HDV-positive individuals had active HDV replication. Among persons who inject drugs (PWID), the prevalence of HDV coinfection was 50.5% (182/360, 95% CI: 45.3%–55.7%), with similar estimates across Europe, compared to 4.7% (52/1109, 95% CI: 3.5%–5.9%) among other participants. During a median follow-up of 10.8 years (interquartile range 5.6–17.8), 82 (34.6%) HDV-positive and 265 (20.1%) HDV-negative individuals died. 41.5% (34/82) of deaths were liver-related in HDV-positive individuals compared to 17.7% (47/265) in HDV-negative individuals. HDV infection was associated with overall mortality (adjusted hazard ratio 1.6; 95% CI 1.2–2.1), liver-related death (2.9, 1.6–5.0) and HCC (6.3, 2.5–16.0). Conclusion: We found a very high prevalence of hepatitis delta among PWID across Europe. Among PLWH who do not inject drugs, the prevalence was similar to that reported from ... |
| Document Type: | article in journal/newspaper |
| Language: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/36625770; info:eu-repo/semantics/altIdentifier/wos/WOS:000918282900001; volume:43; issue:4; firstpage:819; lastpage:828; numberofpages:10; journal:LIVER INTERNATIONAL; https://hdl.handle.net/20.500.11768/152596 |
| DOI: | 10.1111/liv.15519 |
| Availability: | https://hdl.handle.net/20.500.11768/152596; https://doi.org/10.1111/liv.15519; https://onlinelibrary.wiley.com/doi/10.1111/liv.15519 |
| Rights: | info:eu-repo/semantics/openAccess ; license:Creative commons ; license uri:http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Accession Number: | edsbas.6729875D |
| Database: | BASE |